RecruitingNCT07154186
Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients
Impact of Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients
Sponsor
Sohag University
Enrollment
180 participants
Start Date
Sep 4, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to evaluate the impact of the triglyceride-glucose (TyG) index on the angiographic profiling of non-diabetic patients with premature coronary artery disease (CAD).
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age ≥18 years old.
- Both sexes.
- Non-diabetic patients \[no history of diabetes, hemoglobin A1C (HbA1C) < 6.5%, fasting glucose < 126 mg/dL\].
- Confirmed diagnosis of coronary artery disease (CAD) by coronary angiography.
Exclusion Criteria5
- Known diabetes mellitus (type 1 or type 2).
- Previous history of coronary revascularization.
- Severe hepatic or renal dysfunction \[alanine transaminase (ALT)/aspartate aminotransferase (AST) ≥ 5× upper limit of normal (ULN), estimated glomerular filtration rate (eGFR)< 30 mL/min/1.73 m²\].
- Malignant disease, autoimmune disease, or systemic inflammatory disorders.
- Current use of triglyceride-lowering medications.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERCoronary Angiographic Assessment
Coronary angiographic assessment will be performed for all patients.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07154186
Related Trials
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
NCT072582901 location
DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.
NCT0665783313 locations
Product Surveillance Registry
NCT01524276395 locations
Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation
NCT0686315512 locations
Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions
NCT0719069016 locations